BioStock: Chordate Medical can resume migraine study in Finland

Chordate Medical’s treatment, Kinetic Oscillation Stimulation, is currently being evaluated in a clinical study in patients with chronic migraine in Germany and Finland. Due to Covid-19, however, the Finnish part of the migraine study has been paused since March. Last week, Chordate Medical announced that the patient recruitment in Finnish study clinics will be resumed. According to the company, this means that the last patient will be treated in the study during the first quarter of 2021.

Read the full article at biostock.se:
 
https://www.biostock.se/en/chordate-medical-can-resume-migraine-study-in-finland/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se